Roche Reports Topline Data from P-III (CENTERSTONE) Study of Xofluza to Reduce the Transmission of Influenza Virus
Shots:
- The P-III (CENTERSTONE) study assessed the safety & efficacy of single-dose Xofluza (oral), administered within 48hrs. of symptoms onset, for reducing influenza transmission in over 4,000 subjects, incl. otherwise healthy patients (5-64yrs.)
- Study reached its 1EP, showing reduced probability of other household members contracting the virus; safety was favorable without any new concerns. Results will be highlighted at the OPTIONS XII 2024 for the Control of Influenza congress
- Xofluza inhibits the cap-dependent endonuclease protein to block viral replication, lowering the duration of infectiousness. It has shown effectiveness against a broad range of influenza viruses [oseltamivir-resistant & avian strains (H7N9, H5N1)] in preclinical studies
Ref: Roche | Image: Roche
Related News:- Roche’s Xofluza (baloxavir marboxil) Receives EC’s Approval for the Treatment of Influenza in Children Aged ≥1 Year
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
